Tämän jakson äänitiedosto saattaa olla viallinen.
How to fix it?
TIETOJA TÄSTÄ JAKSOSTA
Listen to Tina Wang, Statistician, and Dr. Paul Schuette, Deputy Division Director, in the Office of Biostatistics Division of Analytics and Informatics within FDA’s Center for Drug Evaluation and Research discuss FDA’s experiences with a centralized statistical monitoring tool.
Englanti
Yhdysvallat
HAE EDELLISIÄ EPISODEJA
Hae kanavan FDA CDER Small Business and Industry Assistance (SBIA) Chronicles vanhoja jaksoja.
MUITA jaksoja TÄSSÄ PODCASTISSA
The Role of Pharmacodynamic Biomarkers in Biosimilar Drug Development
Continuous manufacturing (CM) technology has the potential to improve product quality and reliability, lower manufacturing costs, reduce waste, decrease inventory, and increase manufacturing flexibility and agility in response to product demand.
The CDER NextGen Portal (or the “Portal” for short) has made it easier than ever for regulated industry to communicate with the FDA.
FDA Regulation and Quality Considerations for Cannabis and Cannabis-Derived Compounds
The FDA Compounding Incidents Program: Adverse Events Associated with Compounded Drugs from Outsourcing Facilities
Vastuuvapautusilmoitus: Tälle sivulle upotettu podcast ja kuvitus ovat peräisin U.S. Food and Drug Administration, Center for Drug Evaluation and Research:ltä, joka on sen omistajan omaisuutta, eikä se ole sidoksissa Listen Notes, Inc:n tukemaan.
MUOKKAA
Kiitos, kun autoit pitämään podcast-tietokantaa ajan tasalla.
